Rising above the noise: hallmarks of Europe’s leading innovation

The acceleration of innovation and translational biology means that even entrepreneurs with the best ideas face competition for bandwidth. Attracting investor and pharma attention requires companies to differentiate themselves to rise above the noise. At the same time, investors and pharmas report that they are inundated with pitches and must sort through the piles of opportunities, well before they properly vet them or enter due diligence.  

For this year’s Bio€quity Europe conference Scene Setter analysis, BioCentury examined the hallmarks of European companies that “rose above the noise” — either raising over $50 million in venture or announcing a deal with a major pharma during the bear market of 2022-23...